Update on Histological Reporting Changes in Neuroendocrine Neoplasms

Purpose of Review Classification and nomenclature of neuroendocrine neoplasms (NEN) have frequently changed over the last years. These changes reflect both increasing knowledge and international standardisation. Recent Findings The most recent changes in the Gastro-Entero-Pancreatic system induced t...

Full description

Saved in:
Bibliographic Details
Published inCurrent oncology reports Vol. 23; no. 6; p. 65
Main Authors Bräutigam, Konstantin, Rodriguez-Calero, Antonio, Kim-Fuchs, Corina, Kollár, Attila, Trepp, Roman, Marinoni, Ilaria, Perren, Aurel
Format Journal Article
LanguageEnglish
Published New York Springer US 01.06.2021
Springer Nature B.V
Subjects
Biomarkers, Tumor
Clinical trials
Epigenesis, Genetic
Humans
Medicine
Medicine & Public Health
Neuroendocrine Neoplasms (NS Reed
Neuroendocrine Neoplasms (NS Reed, Section Editor)
Neuroendocrine tumors
Neuroendocrine Tumors - classification
Neuroendocrine Tumors - genetics
Neuroendocrine Tumors - pathology
Nomenclature
Oncology
Pancreas
Section Editor
Topical Collection on Neuroendocrine Neoplasms
Transcriptome
Tumors
Pathology
Neuroendocrine tumour
NET
Reporting
NEN
Classification
Online AccessGet full text

Cover

More Information
Summary:Purpose of Review Classification and nomenclature of neuroendocrine neoplasms (NEN) have frequently changed over the last years. These changes reflect both increasing knowledge and international standardisation. Recent Findings The most recent changes in the Gastro-Entero-Pancreatic system induced the concept of well-differentiated NET with high proliferation rate (NET G3), explaining partially the heterogeneity of G3 NEN. Even if the nomenclature in pulmonary NEN is still different, the terms ‘carcinoid’ and ‘atypical carcinoid’ are widely overlapping with NET G1 and NET G2. Molecular data shows an additional heterogeneity both in well-differentiated NET and poorly differentiated NEC. However, no studies are available demonstrating clinical usefulness yet. Summary The heterogeneity of NEN regarding the organ of origin, differentiation and molecular subtypes make development of personalised therapy a challenge needing more international and interdisciplinary collaborations and clinical trials allowing stratification according to biological subgroups.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:1523-3790
1534-6269
1534-6269
DOI:10.1007/s11912-021-01062-6